The paradox of spironolactone: A heart failure treatment with potentially harmful effects

The paradox of spironolactone: A heart failure treatment with potentially harmful effects

Show other versions (1)

Madam, Heart failure (HF) is a multifaceted clinical syndrome arising from a functional or structural cardiac condition that hampers the adequate filling or expulsion of blood into the systemic circulation. It is estimated that heart failure affects around 26 million people globally and significa...

Full description

Bibliographic Details
Main Authors:	Muhammad Roshan, Muhammad Ahmad Nadeem, Sahar Imran Khalfay
Format:	Article
Language:	English
Published:	Pakistan Medical Association 2024-01-01
Series:	Journal of the Pakistan Medical Association
Subjects:	Heart Failure Spironolactone hyperkalemia
Online Access:	http://ojs.jpma.org.pk/index.php/public_html/article/view/10270

Similar Items

The paradox of spironolactone: A heart failure treatment with potentially harmful effects
by: Muhammad Roshan, et al.
Published: (2024-01-01)

Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives
by: Manolis AA, et al.
Published: (2019-12-01)

Furosemide and spironolactone doses and hyponatremia in patients with heart failure
by: Ivan Velat, et al.
Published: (2020-08-01)

Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China—The China PEACE Retrospective Heart Failure Study
by: Yuan Yu, et al.
Published: (2022-10-01)

Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
by: Giuseppe Remuzzi, et al.
Published: (2010-01-01)

Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
by: Tetsuro Tsujimoto, et al.
Published: (2020-12-01)

A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction
by: Mark N. Belkin, et al.
Published: (2021-10-01)

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
by: Yu Wang, BA, et al.
Published: (2020-09-01)

Effect of spironolactone on transmitral diastolic blood flow and course of chronic heart failure with preserved left ventricular ejection fraction
by: V. A. Vasylenko
Published: (2015-10-01)

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
by: Hui‐min Zhou, et al.
Published: (2023-02-01)

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
by: Nobuyuki Enzan, et al.
Published: (2020-02-01)

Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment
by: Manting Choy, et al.
Published: (2022-08-01)

Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
by: Moritz Schnelle, et al.
Published: (2021-10-01)

Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trialsResearch in context
by: Karl-Patrik Kresoja, et al.
Published: (2023-10-01)

Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients
by: Sun Z, et al.
Published: (2023-01-01)

ALDOSTERONE ANTAGONISTS. MODERN VIEWS ON THE MECHANISM OF ACTION AND EFFECTS OF SPIRONOLACTONE
by: V. I. Podzolkov, et al.
Published: (2017-05-01)

The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study
by: Soo Jin Na, et al.
Published: (2022-02-01)

Spironolactone-Induced Agranulocytosis: A Case Report
by: Shu-Hwa Hsiao, et al.
Published: (2003-11-01)

Corrigendum: The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study
by: Soo Jin Na, et al.
Published: (2022-04-01)

Analysis of spironolactone polymorphs in active pharmaceutical ingredients and their effect on tablet dissolution profiles
by: Renata Cunha de Resende, et al.

Potential Ameliorating Role of Spironolactone in Trastuzumab-induced Cardiotoxicity: A Narrative Review
by: Amir Ghabousian, et al.
Published: (2021-11-01)

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction
by: Luis Ortega‐Paz, et al.
Published: (2023-02-01)

Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk
by: Jun-Feng Li, et al.
Published: (2023-01-01)

Impact of Hyperkalemia in Heart Failure and Reduced Ejection Fraction: A Retrospective Study
by: Andrea Lopez-López, et al.
Published: (2023-05-01)

Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial
by: Job A. J. Verdonschot, et al.
Published: (2021-08-01)

Spironolactone in chronic hemodialysis patients improves cardiac function
by: Taheri Shahram, et al.
Published: (2009-01-01)

Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT
by: Eduard Shantsila, et al.
Published: (2020-07-01)

Hyperkalemia in Heart Failure: Probably Not O“K”
by: Marat Fudim, et al.
Published: (2018-06-01)

Novel role of spironolactone in the therapy of resistant hypertension: Spironolactone and resistant hypertension
by: Dragojević-Simić Viktorija, et al.
Published: (2019-01-01)

Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial
by: Eduard Shantsila, et al.
Published: (2020-09-01)

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
by: Nappi J, et al.
Published: (2011-06-01)

Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer
by: Jonathan Slawik, et al.
Published: (2020-10-01)

Hiperpotassemia na vigência de espironolactona em pacientes com insuficiência cardíaca descompensada Hyperkalemia during spironolactone use in patients with decompensated heart failure
by: Marcelo Villaça Lima, et al.
Published: (2008-09-01)

Serum Potassium Levels and Mortality in Hospitalized Heart Failure Patients
by: Bo-Ping Huang, et al.
Published: (2023-08-01)

Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial
by: Diogo Santos‐Ferreira, et al.
Published: (2024-02-01)

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure
by: C McKenna, et al.
Published: (2010-05-01)

Association of spironolactone treatment and arterial stiffness and cardiovascular disease in hypertensive patients
by: Fanfang Zeng, et al.
Published: (2019-06-01)

Effects of spironolactone on extrasystoles and heart rate variability in haemodialysis patients: a randomised crossover trial
by: Michael Eklund, et al.
Published: (2021-01-01)

Possible role of Spironolactone in a sample of Iraqi patients with acute central serous chorioretinopathy
by: Marwa Majeed Hameed, et al.
Published: (2022-05-01)

Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat
by: Catherine J. Leader, et al.
Published: (2020-05-01)